IL283960B2 - History of deuterated 3-hydroxy-3-methoxymethyl-pergan-21-(h1-imidazol-1-yl)-20-one and pharmaceutical preparations containing them - Google Patents

History of deuterated 3-hydroxy-3-methoxymethyl-pergan-21-(h1-imidazol-1-yl)-20-one and pharmaceutical preparations containing them

Info

Publication number
IL283960B2
IL283960B2 IL283960A IL28396021A IL283960B2 IL 283960 B2 IL283960 B2 IL 283960B2 IL 283960 A IL283960 A IL 283960A IL 28396021 A IL28396021 A IL 28396021A IL 283960 B2 IL283960 B2 IL 283960B2
Authority
IL
Israel
Prior art keywords
disorders
compound
disorder
compound according
status epilepticus
Prior art date
Application number
IL283960A
Other languages
English (en)
Hebrew (he)
Other versions
IL283960A (en
IL283960B1 (en
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of IL283960A publication Critical patent/IL283960A/en
Publication of IL283960B1 publication Critical patent/IL283960B1/en
Publication of IL283960B2 publication Critical patent/IL283960B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/007—Steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
IL283960A 2018-12-17 2019-12-17 History of deuterated 3-hydroxy-3-methoxymethyl-pergan-21-(h1-imidazol-1-yl)-20-one and pharmaceutical preparations containing them IL283960B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862780703P 2018-12-17 2018-12-17
PCT/US2019/066923 WO2020131918A1 (en) 2018-12-17 2019-12-17 Organic compounds

Publications (3)

Publication Number Publication Date
IL283960A IL283960A (en) 2021-07-29
IL283960B1 IL283960B1 (en) 2025-05-01
IL283960B2 true IL283960B2 (en) 2025-09-01

Family

ID=71100855

Family Applications (1)

Application Number Title Priority Date Filing Date
IL283960A IL283960B2 (en) 2018-12-17 2019-12-17 History of deuterated 3-hydroxy-3-methoxymethyl-pergan-21-(h1-imidazol-1-yl)-20-one and pharmaceutical preparations containing them

Country Status (11)

Country Link
US (1) US12325726B2 (https=)
EP (1) EP3897656A4 (https=)
JP (1) JP7645797B2 (https=)
KR (1) KR102931436B1 (https=)
CN (1) CN113226326B (https=)
AU (1) AU2019406803B2 (https=)
BR (1) BR112021011765A2 (https=)
CA (1) CA3121636A1 (https=)
IL (1) IL283960B2 (https=)
MX (1) MX2021007142A (https=)
WO (1) WO2020131918A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10562930B1 (en) 2018-08-31 2020-02-18 Praxis Precision Medicines, Inc. Salts and crystal forms of GABAA positive allosteric modulator
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
WO2021168106A1 (en) * 2020-02-18 2021-08-26 Praxis Precision Medicines, Inc. Deuterated neurosteroid
JP2023539125A (ja) * 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2023159094A2 (en) * 2022-02-16 2023-08-24 Praxis Precision Medicines, Inc. PROCESS OF MAKING 3α-HYDROXY-3β-METHOXYMETHYL-21-(1'- IMIDAZOLYL)-5α-PREGNAN-20-ONE

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034002A1 (en) * 1999-04-29 2004-02-19 Euro-Celtique S.A. 3Alpha-hydroxy-3beta-methoxymethyl-substituted steroids and the use thereof
US20120276196A1 (en) * 2005-06-09 2012-11-01 Euro-Celtique S.A. Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof
WO2016134301A2 (en) * 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5232917A (en) 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
KR100338287B1 (ko) 1994-02-14 2002-11-30 푸르듀 파머 리미티드 감마-아미노부티르산a수용체의알로오스테리조절용안드로스탄및프레그난
US5939545A (en) 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
CN1087725C (zh) * 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
WO2005105822A2 (en) 2004-04-23 2005-11-10 Euro-Celtique S.A. 3-alpha-hydroxy 21-n- heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof
US20060074059A1 (en) 2004-08-26 2006-04-06 Goliber Philip A Isomorphic crystalline habits of 3alpha-hydroxy-21-(1'-imidazolyl)-3beta-methoxymethyl-5alpha-pregnane-20-one
JP6470258B2 (ja) 2013-04-17 2019-02-13 セージ セラピューティクス， インコーポレイテッド １９−ノルｃ３，３−ジ置換ｃ２１−ｎ−ピラゾリルステロイドおよびその使用方法
ME03809B (me) * 2014-10-16 2021-04-20 Sage Therapeutics Inc KOMPOZICIJE I POSTUPCI ZA LEČENJE POREMEĆAJA CNS-a
CN105985396A (zh) * 2015-02-16 2016-10-05 苏州泽璟生物制药有限公司 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物
EP3720867A1 (en) 2017-12-08 2020-10-14 Sage Therapeutics, Inc. Deuterated 21 -[4-cyano-pyrazol-1 -yl]-19-nor-pregan-3. alpha-ol-20-one derivatives for treating cns disorders
AU2019406803B2 (en) 2018-12-17 2025-04-24 Intra-Cellular Therapies, Inc. Organic compounds
JP2023539125A (ja) 2020-08-20 2023-09-13 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040034002A1 (en) * 1999-04-29 2004-02-19 Euro-Celtique S.A. 3Alpha-hydroxy-3beta-methoxymethyl-substituted steroids and the use thereof
US20120276196A1 (en) * 2005-06-09 2012-11-01 Euro-Celtique S.A. Pharmaceutical Compositions of a Neuroactive Steroid and Methods of Use Thereof
US20170240589A1 (en) * 2014-10-16 2017-08-24 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016134301A2 (en) * 2015-02-20 2016-08-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof

Also Published As

Publication number Publication date
MX2021007142A (es) 2021-08-11
JP7645797B2 (ja) 2025-03-14
JP2022513933A (ja) 2022-02-09
AU2019406803A1 (en) 2021-07-08
KR102931436B1 (ko) 2026-02-25
BR112021011765A2 (pt) 2021-08-31
CN113226326A (zh) 2021-08-06
CA3121636A1 (en) 2020-06-25
US20220073558A1 (en) 2022-03-10
WO2020131918A1 (en) 2020-06-25
CN113226326B (zh) 2024-09-20
IL283960A (en) 2021-07-29
EP3897656A1 (en) 2021-10-27
AU2019406803B2 (en) 2025-04-24
EP3897656A4 (en) 2022-09-21
KR20210105934A (ko) 2021-08-27
US12325726B2 (en) 2025-06-10
IL283960B1 (en) 2025-05-01

Similar Documents

Publication Publication Date Title
AU2019406803B2 (en) Organic compounds
WO2022040545A1 (en) Organic compounds
US20190083420A1 (en) Methods of using (2r, 6r)-hydroxynorketamine and (2s, 6s)-hydroxynorketamine in the treatment of depression, anxiety, anhedonia, fatigue, suicidal ideation, and post traumatic stress disorders
JP2022548104A (ja) ピリジン窒素酸化物及びその製造方法と使用
CN114206899A (zh) 3-羟基-5-孕烷-20-酮衍生物及其用途
CA3182354A1 (en) Methyl 2-(fluoromethyl)-5-oxo-4-phenyl-4,5,6,7-tetrahydro-1h-cyclopenta[b]pyridine-3-carboxylates and methyl 2-(fluoromethyl)-5-oxo-4-phenyl-1,4,5,7-tetrahydrofuro[3,4-b]pyridine-3-carboxylates as cav1.2 activators
CN103635446B (zh) 戊四唑衍生物
JP2021519276A (ja) Ｄ−β−ヒドロキシ酪酸の重水素化類似体およびその使用
JP2021500309A (ja) 気分障害のための新規ガンマアミノ酪酸型受容体モジュレーター
JP7750582B2 (ja) 水溶性アロプレグナノロン誘導体及びその製造方法並びに用途
RU2809023C2 (ru) Органические соединения
HK40058207A (en) Organic compounds
EP4165048B1 (en) Methyl 2-methyl-5-oxo-1,4,5,7-tetradhydrofuro[3,4- b]pyridine-3-carboxylate compounds as cav1.2 activators
CA2994153A1 (en) Deuterated morphinan compounds for use in treating agitation
HK40058207B (zh) 有机化合物
WO2023049295A1 (en) Deuterated positive nmda-modulating compounds and methods of use thereof
JP2024545200A (ja) ＣａＶ１．２活性剤としてのピリジン－３－カルボキシレート化合物
WO2022189859A1 (en) Fatty acid-bifunctional degrader conjugates and their methods of use